Our Research Priorities
Drive Strategic Investments
February 11, 2015
Geneticist Dr. Tatiana Foroud explains how the study of Parkinson's genetics can help develop new therapies.
February 04, 2015
The Foundation has united three powerhouse pharmaceutical companies for a pre-competitive consortium to advance LRRK2 inhibitors as potential disease-modifying medications.
UPCOMING FUNDING PROGRAM DEADLINES
Deadline: Pre-Proposals Due: December 3, 2014 Ė 6pm US ET
One-to-three-year grants to develop robust and precise biomarkers (imaging, physiological, genomic, biochemical assays, etc.) and/or clinical outcome measures that can inform therapeutic trial designs and interpretation of trial results.† The biomarkers and outcome measures should be aimed at informing clinical trial decisions.
Deadline: Letters of Intent Due: March 19, 2014
Two-year grants to stimulate collaborative analyses across the Alzheimerís disease (AD) and Parkinsonís disease (PD) research enterprises.